
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6403/publications.pdf Version: 2024-02-01



LUNC HUN KANC

#	Article	IF	CITATIONS
1	Safe use of opioids. Journal of the Korean Medical Association, 2022, 65, 57-65.	0.3	1
2	Palliative Sedation in End-of-Life Patients in Eastern Asia: A Narrative Review. Cancer Research and Treatment, 2022, 54, 644-650.	3.0	3
3	Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study. Cancers, 2022, 14, 1950.	3.7	3
4	Survey of Opioid Risk Tool Among Cancer Patients Receiving Opioid Analgesics. Journal of Korean Medical Science, 2022, 37, .	2.5	0
5	Modified FOLFIRINOX versus S-1 as second-line chemotherapy in patients with gemcitabine-failed metastatic pancreatic cancer: A randomized phase III trial (MPACA-3) Journal of Clinical Oncology, 2021, 39, 4119-4119.	1.6	1
6	Korean Version of the Patient Dignity Inventory: Translation and Validation in Patients With Advanced Cancer. Journal of Pain and Symptom Management, 2021, 62, 416-424.e2.	1.2	0
7	Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). European Journal of Cancer, 2021, 157, 21-30.	2.8	18
8	Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large Bâ€cell lymphoma. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 2211-2219.	7.3	22
9	Community Care for Cancer Patients in Rural Areas: An Integrated Regional Cancer Center and Public Health Center Partnership Model. The Korean Journal of Hospice and Palliative Care, 2021, 24, 226-234.	0.7	2
10	A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities. Oncologist, 2020, 25, e186-e193.	3.7	10
11	Association of illness understanding with advance care planning and end-of-life care preferences for advanced cancer patients and their family members. Supportive Care in Cancer, 2020, 28, 2959-2967.	2.2	25
12	Debatable Issues in Palliative Sedation; Authors' Reply to the Response by Robert Twycross. Journal of Pain and Symptom Management, 2020, 59, e2-e3.	1.2	0
13	rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects. Cancers, 2020, 12, 3120.	3.7	8
14	Regorafenib in patients with advanced Childâ€Pugh B hepatocellular carcinoma: A multicentre retrospective study. Liver International, 2020, 40, 2544-2552.	3.9	32
15	Interference with daily functioning by breakthrough pain in patients with cancer. Supportive Care in Cancer, 2020, 28, 5177-5183.	2.2	8
16	The Impacts of Prognostic Awareness on Mood and Quality of Life Among Patients With Advanced Cancer. American Journal of Hospice and Palliative Medicine, 2020, 37, 904-912.	1.4	18
17	Clinical Practice Guideline for Care in the Last Days of Life. The Korean Journal of Hospice and Palliative Care, 2020, 23, 103-113.	0.7	6
18	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG) Journal of Clinical Oncology, 2020, 38, 4624-4624.	1.6	0

#	Article	IF	CITATIONS
19	The prognostic significance of the advanced lung cancer inflammation index(ALI) in patients with advanced biliary tract cancer: A retrospective study Journal of Clinical Oncology, 2020, 38, e16613-e16613.	1.6	0
20	The Attitudes of Physicians and the General Public toward Prognostic Disclosure of Different Serious Illnesses: a Korean Nationwide Study. Journal of Korean Medical Science, 2020, 35, e401.	2.5	0
21	Clinical Patterns of Continuous and Intermittent Palliative Sedation in Patients With Terminal Cancer: A Descriptive, Observational Study. Journal of Pain and Symptom Management, 2019, 58, 65-71.	1.2	17
22	Attitudes of the General Public, Cancer Patients, Family Caregivers, and Physicians Toward Advance Care Planning: A Nationwide Survey Before the Enforcement of the Life-Sustaining Treatment Decision-Making Act. Journal of Pain and Symptom Management, 2019, 57, 774-782.	1.2	25
23	Sedation for terminally ill cancer patients. Medicine (United States), 2019, 98, e14278.	1.0	12
24	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. Journal of Cancer, 2019, 10, 6185-6190.	2.5	7
25	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 501-508.	2.3	6
26	Preference and Performance Fidelity of Modified Korean Physician Order for Life-Sustaining Treatment (MK-POLST) Items in Hospice Patients with Cancer. The Korean Journal of Hospice and Palliative Care, 2019, 22, 198-206.	0.7	1
27	Priorities of a "good death―according to cancer patients, their family caregivers, physicians, and the general population: a nationwide survey. Supportive Care in Cancer, 2018, 26, 3479-3488.	2.2	46
28	Attitudes toward early palliative care in cancer patients and caregivers: a Korean nationwide survey. Cancer Medicine, 2018, 7, 1784-1793.	2.8	22
29	Development and validation of the quality care questionnaire –palliative care (QCQ-PC): patient-reported assessment of quality of palliative care. BMC Palliative Care, 2018, 17, 40.	1.8	13
30	The impact of caregiver's role preference on decisional conflicts and psychiatric distresses in decision making to help caregiver's disclosure of terminal disease status. Quality of Life Research, 2018, 27, 1571-1581.	3.1	6
31	Using primary tumor volumetry to predict treatment outcome for patients with oropharyngeal cancer who were treated with definitive chemoradiotherapy. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e21-e28.	1.1	1
32	Discordance between Physician and the General Public Perceptions of Prognostic Disclosure to Children with Serious Illness: a Korean Nationwide Study. Journal of Korean Medical Science, 2018, 33, e327.	2.5	7
33	Compassion is a key quality for palliative care teams. Cancer Medicine, 2018, 7, 5325-5326.	2.8	2
34	Comparison of attitudes towards five end-of-life care interventions (active pain control, withdrawal) Tj ETQq0 0 () rgBT /O 1.9	verlock 10 Tf 5 20
35	caregivers, physicians and the general Korean population. BMJ Open, 2018, 8, e020519. Attenuated FOLFIRINOX in the salvage treatment of gemcitabineâ€refractory advanced pancreatic cancer: a phase II study. Cancer Communications, 2018, 38, 1-8.	9.2	23
36	Craving Behavior from Opioid Addiction Controlled with Olanzapine in an Advanced Cancer Patient: A Case Report. Journal of Palliative Medicine, 2018, 21, 1367-1370.	1.1	8

#	Article	IF	CITATIONS
37	Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. Korean Journal of Internal Medicine, 2018, 33, 383-390.	1.7	9
38	Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. Cancer Research and Treatment, 2018, 50, 488-494.	3.0	28
39	Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report. Cancer Research and Treatment, 2018, 50, 1458-1461.	3.0	13
40	Successful Treatment with Transdermal Buprenorphine Patch in Opioid-Dependent Cancer Patients: Case Series. The Korean Journal of Hospice and Palliative Care, 2018, 21, 152-157.	0.7	1
41	Qualitative Study on the Perceptions of Terminally Ill Cancer Patients and Their Family Members Regarding End-of-Life Experiences Focusing on Palliative Sedation. Journal of Pain and Symptom Management, 2017, 53, 1010-1016.	1.2	17
42	Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. Oncologist, 2017, 22, 293-303.	3.7	5
43	Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. Oncologist, 2017, 22, 1354-1361.	3.7	24
44	Molecular characterization of urothelial carcinoma of bladder and upper urinary tract Journal of Clinical Oncology, 2017, 35, 361-361.	1.6	1
45	A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. Oncotarget, 2017, 8, 47007-47019.	1.8	26
46	Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer. Journal of Cancer, 2016, 7, 1711-1715.	2.5	6
47	Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. British Journal of Cancer, 2016, 114, 381-387.	6.4	56
48	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Supportive Care in Cancer, 2016, 24, 301-309.	2.2	11
49	Gender Differences in Hiccup Patients: Analysis of Published Case Reports and Case-Control Studies. Journal of Pain and Symptom Management, 2016, 51, 278-283.	1.2	25
50	Chemotherapy versus best supportive care in patients with advanced biliary tract carcinoma: A propensity score-matched analysis Journal of Clinical Oncology, 2016, 34, 316-316.	1.6	1
51	Is There a Role for Adjuvant Therapy in RO Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis. Cancer Research and Treatment, 2016, 48, 1274-1285.	3.0	14
52	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma Journal of Clinical Oncology, 2016, 34, 355-355.	1.6	4
53	Attenuated FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for the Koreans (Asian population) with gemcitabine-resistant or –refractory advanced pancreatic cancer Journal of Clinical Oncology, 2016, 34, e15731-e15731.	1.6	0
54	Changes in health-related quality of life and quality of care among terminally ill cancer patients and survival prediction: Multicenter prospective cohort study. Palliative and Supportive Care, 2015, 13, 1103-1111.	1.0	10

#	Article	IF	CITATIONS
55	Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. Blood Research, 2015, 50, 242.	1.3	15
56	Long-Term Intermittent Palliative Sedation for Refractory Symptoms at the End of Life in Two Cancer Patients. Journal of Palliative Medicine, 2015, 18, 807-810.	1.1	16
57	Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective study Journal of Clinical Oncology, 2015, 33, 9601-9601.	1.6	Ο
58	Comparison of Failure Patterns Between Conventional and Intensity-modulated Radiotherapy for Stage III and IV Head and Neck Squamous Cell Carcinoma. Anticancer Research, 2015, 35, 6833-40.	1.1	5
59	The Understanding of Terminal Cancer and Its Relationship with Attitudes toward End-of-Life Care Issues. Medical Decision Making, 2014, 34, 720-730.	2.4	11
60	Simvastatin plus capecitabine–cisplatin versus placebo plus capecitabine–cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. European Journal of Cancer, 2014, 50, 2822-2830.	2.8	79
61	Physical Symptoms and Psychiatric, Social, Spiritual and Economical Care Needs of Patients under Home-based Cancer Service. The Korean Journal of Hospice and Palliative Care, 2014, 17, 216-222.	0.7	6
62	Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study. Cancer Research and Treatment, 2014, 46, 331-338.	3.0	6
63	Natural history of untreated patients who had metastatic biliary tract cancer (BTC) with good performance status (PS) Journal of Clinical Oncology, 2014, 32, e15106-e15106.	1.6	0
64	Clinical significance of the neutrophil–lymphocyte ratio in venous thromboembolism patients with lung cancer Journal of Clinical Oncology, 2014, 32, e19118-e19118.	1.6	0
65	The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer Journal of Clinical Oncology, 2014, 32, e18550-e18550.	1.6	0
66	The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives. Supportive Care in Cancer, 2013, 21, 1437-1444.	2.2	48
67	Comprehensive approaches to managing delirium in patients with advanced cancer. Cancer Treatment Reviews, 2013, 39, 105-112.	7.7	39
68	Changes in Symptom Intensity Among Cancer Patients Receiving Outpatient Palliative Care. Journal of Pain and Symptom Management, 2013, 46, 652-660.	1.2	68
69	Treatment of Dexamethasone-Induced Hiccup in Chemotherapy Patients by Methylprednisolone Rotation. Oncologist, 2013, 18, 1229-1234.	3.7	28
70	The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives. , 2013, 21, 1437.		1
71	Corticosteroid Rotation to Alleviate Dexamethasone-Induced Hiccup: A Case Series at a Single Institution. Journal of Pain and Symptom Management, 2012, 43, 625-630.	1.2	31
72	Targeted agent use in patients with cancer at the end of life Journal of Clinical Oncology, 2012, 30, 215-215.	1.6	1

#	Article	IF	CITATIONS
73	Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Investigational New Drugs, 2010, 28, 343-349.	2.6	15
74	Phase II trial of S-1 in combination with gemcitabine for chemo-naÃ ⁻ ve patients with locally advanced or metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 64, 707-713.	2.3	28
75	Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma Blood, 2006, 108, 4670-4670.	1.4	0